Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc. (symbol: THTX) is a biopharmaceutical company that markets prescription products across the United States, Europe, and Canada. Founded in 1993 and headquartered in Montreal, Canada, the company is dedicated to addressing the unmet medical needs of patients living with HIV and other serious health conditions.
Core Products:
- EGRIFTA and EGRIFTA SV: These products help reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their quality of life.
- Trogarzo: A vital injection treatment for multidrug-resistant HIV-1 infected patients, offering hope to those who have limited treatment options.
Pipeline Products:
- F8 Formulation: A promising treatment for HIV-associated lipodystrophy, currently in development.
- TH-1902: A potential breakthrough in the treatment of triple-negative breast cancer.
- TH-1904: Targeting ovarian cancer, another pipeline product with significant potential.
Theratechnologies generates significant revenue from its relationship with RxCrossroads, a major customer based in the United States. The company's strategic partnerships and innovative products showcase its commitment to improving patient outcomes in serious medical conditions. With a dedicated focus on research and development, Theratechnologies continues to make strides in the biopharmaceutical industry.
Theratechnologies reported a strong second quarter for fiscal 2024, with revenue reaching $22 million, a 25% year-over-year increase. The company achieved a positive net income of $1 million and an Adjusted EBITDA of $5.5 million. For the full fiscal year 2024, Theratechnologies affirmed its revenue guidance between $87 million and $90 million, with Adjusted EBITDA projected between $13 million and $15 million.
EGRIFTA SV® sales saw a significant rise of 49.3% year-over-year, whereas Trogarzo® sales dropped by 13.1%. The company has also progressed in its oncology pipeline, completing the recruitment for the second cohort of a Phase 1 trial for sudocetaxel zendusortide.
Recently, Theratechnologies reorganized its preclinical oncology research activities and presented promising Phase 1 data at the ASCO 2024 meeting. General and administrative expenses and selling expenses saw reductions, contributing to improved financial performance. The cash position as of May 31, 2024, was $36.03 million, providing sufficient liquidity for the next 12 months.
Theratechnologies, a biopharmaceutical company, announced it will report its financial results and provide a business update for the second quarter ending May 31, 2024. The announcement will be made on July 10, 2024, at 8:30 a.m. ET. The call will be hosted by President and CEO Paul Lévesque, alongside other members of the management team including CFO Philippe Dubuc, CMO Christian Marsolais, and Global Commercial Officer John Leasure. Participants are encouraged to join the call early. Dial-in and replay information is available for interested parties.
Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
The study highlighted a unique, multimodal mechanism of action and a favorable safety profile. Notably, 44% of the female cancer patients achieved a clinical benefit rate.
The company is now moving into Part 3 of the Phase 1 trial, focusing on dose optimization.
Theratechnologies Inc. held its annual meeting of shareholders, where candidates for the Board of Directors were elected and KPMG LLP was appointed as auditors. The voting results showed high support for all candidates, with Frank Holler becoming the new Chair of the Board.
Theratechnologies will present long-term efficacy, safety, and pharmacokinetic data on the use of TH1902 in solid tumors at the 2024 ASCO Meeting. The presentation will focus on the Phase 1 clinical trial of sudocetaxel zendusortide in patients with cancers that have high SORT1 expression. Part 3 of the trial in advanced ovarian cancer is ongoing, providing valuable insights into the novel peptide-drug conjugate.
FAQ
What does Theratechnologies Inc. specialize in?
Where are Theratechnologies' products marketed?
What are the main products offered by Theratechnologies?
What are Theratechnologies' pipeline products?
When was Theratechnologies Inc. founded?
Where is Theratechnologies Inc. headquartered?
Who is a major customer of Theratechnologies?
What is the significance of Trogarzo?
How does EGRIFTA benefit HIV patients?
What is Theratechnologies' approach to innovation?
